Please assess the completion status of the following clinical trial:

Trial Title: Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years.~* HIV-1/2 infected patients with Pulmonary TB. This includes sputum smear positive disease.~* Initially smear negative but Xpert-MTB positive or LPA positive taken as a surrogate marker for culture positivity (e.g. miliary TB, Mediastinal adenitis and Chest x-ray with persistent abnormality after antibiotics). as BACTEC (Becton-Dickinson) has been phased out ,Final inclusion will only be patients positive by LJ culture~* Persistent X-ray abnormality will be included for allocation. However final inclusion into both ITT and efficacy analysis will depend on positivity in LJ culture.~* Living within 40 km radius from the nearest sub centre of TRC and willing for attendance as prescribed.~* Likely to remain in the same area for at least one and half years after start of treatment.~* Willing for house visits and surprise checks.~* Willing to participate and give informed consent after going through the terms and conditions of the trial.~Exclusion Criteria:~* Patients with known hypersensitivity to rifampicin~* Pregnancy and lactation at initial presentation~* Major complications like HIV encephalopathy, renal dysfunction (serum creatinine \> 1.5 mg% in the absence of dehydration) or jaundice (serum bilirubin \> 2 mgs% along with SGOT /SGPT elevation \> 2.5 times the upper limit of normal).~* Previous anti-tuberculosis treatment for more than 1 month. Prophylaxis (non-rifampicin containing regimen) will not be considered as prior antituberculosis treatment.~* Moribund, bedridden or unconscious patients.~* Co-morbid conditions like uncontrolled diabetes mellitus, cardiac failure, and malignancy at initial presentation.~* Major psychiatric illness.~* Patients on second line ART, mainly protease inhibitors, at initial presentation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2EHRZ3/4HR3 (Type: ACTIVE_COMPARATOR): Regimen 3. Intermittent - 2EHRZ3/4HR3 (E 1200mg, H 600 mg, R 450/600 mg depending on Weight \<60, 600 mg for 60 kg or more, Z 1500 mg given thrice weekly)
- 2EHRZ7/4HR7 (Type: EXPERIMENTAL): Regimen 1. Daily - 2EHRZ7/4HR7 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight \<60, 600 mg for 60 kg or more, Z 1500 mg daily)
- 2EHRZ7/4HR3 (Type: EXPERIMENTAL): Regimen 2. Part Daily - 2EHRZ7/4HR3 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight \<60, 600 mg for 60 kg or more, Z 1500 mg daily in the intensive phase followed by H-600 mg ,R-450/600 mg in the continuation phase thrice weekly)

Based on this trial design, predict the completion outcome and termination type (if applicable).